

DATA SHEET
Hsa-miR-17Probe

Catalog No	Description
HM017-100	One vial of 0.650 ml of probe in hybridization buffer

Analyte Specific Reagent. Analytical and performance characteristics are not established.

Doc. No. 932-HM017-100 Rev : D
Date of release: 11-Aug-2020

Description

The Hsa-miR-17 probe has been designed from mature human miR-17 sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

Specifications

The Hsa-miR-17 identifies mature miR-17 sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

Storage and Handling

Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

Precautions:

For professional use. The probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

Quality Control

Each lot of this micro RNA probe is tested by *In Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

References

1. Lorio MV and Croce CM. (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. **EMBO Mol Med** 4, 143–159.
2. Chen PS, Su JL, and Hung MC. (2012). Dysregulation of Micro RNAs in cancer. **Journal of Biomedical Science**, 19:90.
3. Nuovo GJ. (2008). In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. **Methods** 44,39–46.
4. Song R. et al. (2010). *In situ* hybridization detection of microRNAs. **Methods Mol Biol.** 629, 287-94.
5. Matsubara H, et al., Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. **Oncogene** 2007;26:6099–105

BioGenex

48810 Kato Road, Suite 100E & 200E
Fremont, CA 94538
Tel : +1 (800) 421-4149, Fax: +1 (510) 824-1490,
support@biogenex.com

6. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, et al.. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. *Cancer Res.*2004;64:3087-95
7. Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, et al. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. *Leuk. Lymphoma.* 2007;48:410-12
8. Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. *Cancer Sci.* 2007;98:1482-90
9. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al., A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc. Natl. Acad. Sci. USA.* 2006;103:2257-61.
10. Luo H, et al, (2012). Up-regulated miR-17 promotes cell proliferation, tumour growth and cell cycle progression by targeting the RND3 tumour suppressor gene in colorectal carcinoma. *Biochem. J.* 442(2):311-21

BioGenex Quality Control Testing Conditions

Parameter	Conditions used
Control Tissue	PROSTATE Carcinoma.,COLON Carcinoma.(FB-HM017)
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues